Titlebook: Acute Myelogenous Leukemia; Genetics, Biology an Lalitha Nagarajan Book 2010 The Editor(s) (if applicable) and The Author(s), under exclusi

BLA

Chromosomal Translocations in AML: Detection and Prognostic Significance,978-3-319-94827-0

誰(shuí)在削木頭

Lineage-Specific Transcription Factor Aberrations in AML,978-3-642-57090-2

是突襲

,Proleukemic RUNX1 and CBFβ Mutations in the Pathogenesis of Acute Leukemia,978-3-642-71113-8

Indicative

Apoptosis in Leukemias: Regulation and Therapeutic Targeting,978-3-662-58094-3

內(nèi)部

0927-3042 he hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered. .978-1-4419-1299-2978-0-387-69259-3Series ISSN 0927-3042 Series E-ISSN 2509-8497

捐助

心痛

E. Gwinner,I. Schwabl-Benzingerrons of two different genes on the same or different chromosome. Most of the fusion genes described in hematological malignancies are transcription factor genes and tyrosine kinases, conferring proliferative advantage to the leukemic clone.

Tdd526

農(nóng)學(xué)

人類(lèi)學(xué)家

https://doi.org/10.1007/b137573. Together they contribute to approximately one-third of acute myelogenous leukemia (AML) and one-quarter of acute lymphoblastic leukemia (ALL) cases, making RUNX1 and CBFβ the most frequently affected genes known in the pathogenesis of acute leukemia. Investigating the mechanisms by which RUNX1, CB